Aspirin

Aspirin use associated with reduction in cardiovascular events but increase in bleeding risk

1. In this systematic review and meta-analysis, while aspirin use among patients without cardiovascular disease was associated with fewer adverse cardiovascular events, it was not associated with a reduction in all-cause mortality. 2. The use of aspirin in patients without cardiovascular disease was associated with increased risk of major bleeding. Evidence Czytaj więcej…

Cardiology

Quick Take: Risk Prediction Tools to Improve Patient Selection for Carotid Endarterectomy Among Patients With Asymptomatic Carotid Stenosis

2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials is available now in paperback and e-book editions. This text summarizes the key trials in: General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and Czytaj więcej…

Cardiology

Medication co-payment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events

1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Czytaj więcej…

alteplase

Low-dose intracoronary alteplase unlikely to improve outcomes in STEMI patients treated with primary PCI

1. In this randomized controlled trial, low-dose intracoronary alteplase given early during primary percutaneous coronary intervention (PCI) for acute ST-Elevation Myocardial Infarction (STEMI) did not reduce microvascular obstruction. 2. Health related quality of life was not improved with low-dose intracoronary alteplase. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute coronary Czytaj więcej…

Cardiology

The REDUCE-IT trial: Icosapent ethyl reduces ischemic event risk in patients with hypertriglyceridemia despite statin use

1. After a median follow-up of 4.9 years, patients with elevated triglyceride levels despite statin use treated with icosapent ethyl had a lower risk of cardiovascular adverse events compared to patients in a placebo group. 2. Hospitalization for atrial fibrillation or flutter occurred in more patients treated with icosapent ethyl Czytaj więcej…